In the pursuit of advanced preclinical research for renal diseases, Prisys Biotech offers an array of specialized non-human primate (NHP) models built to support the development of innovative therapies for both acute and chronic kidney disease (AKI/CKD). As a specialized contract research organization (CRO), Prisys provides renal disease models that mirror human pathological conditions closely enough to carry a translational result, which is what a drug development program needs from them.
Why Non-Human Primate Models For Kidney Disease Research
Kidney disease covers a wide range of acute and chronic conditions and affects millions of people globally. The pathology is complex, and a model has to replicate human kidney function and disease progression rather than approximate it. Non-human primates suit renal research because of their physiological and genetic similarities to humans, which raises the reliability of preclinical data and the predictability of therapeutic outcomes.
The practical version of that argument is pharmacological. A biologic that binds its target in humans may not bind the rodent ortholog at all, so a monkey study is where that question gets settled, and settling it before a first-in-human trial is cheaper than discovering it during one. Species selection also settles the readouts, since the analytes measured in the monkey are the ones a program can carry into a clinical protocol.
Prisys Biotech's Renal Disease Model Portfolio
Prisys Biotech offers a suite of NHP(monkey) Disease Models covering a wide range of kidney pathologies, each built to support the preclinical evaluation of a therapeutic intervention.
- Renal ischemia and reperfusion models. These simulate acute kidney injury through ischemia-reperfusion protocols and show the injury mechanisms and recovery processes that matter for Acute Kidney Injury drug development.
- Obstructive CKD and AKI-to-CKD transition models. These let researchers study the move from acute kidney injury into chronic kidney disease, which is the progressive pattern renal damage follows in humans.
- Renal fibrosis models. Prisys provides both interstitial and glomerular fibrosis models, which allow investigation of fibrotic pathways and evaluation of anti-fibrotic therapies for chronic kidney diseases.
- Systemic complications. Cardiovascular and systemic complications such as cardio-renal syndrome and IgA nephropathy are common in kidney disease patients, and Prisys' models incorporate these comorbidities, which gives a view of the systemic effects of kidney disease.
Choosing inside the portfolio usually comes down to the stage of the program. An acute model answers a mechanism question quickly, and a transition model answers the harder one about whether an injury consolidates into chronic disease. Fibrosis models sit at the end of that sequence, where the question is whether a treatment can slow a process that already has momentum.
Diagnostic Tools For Renal Research
Beyond the models, Prisys Biotech uses diagnostic tools to sharpen research precision. Renal CT and MRI imaging through the Clinical Imaging platform assess kidney morphology and pathology in real time, and imaging answers a question histology cannot, because it shows the whole organ repeatedly in the same animal and a lesion can be followed over time. Glomerular filtration rate (GFR) assessment belongs in the same renal workup, because accurate GFR measurement is what monitoring kidney function depends on. Biomarker analysis covers human biomarkers, which supports the development of targeted therapies and is where the translational value of an NHP study becomes concrete: the same analyte can be followed in the animal and in the patient.
The UUO Model In Cynomolgus Monkeys
Prisys Biotech has documented work on models that support CKD research. A recent study used them to simulate chronic kidney conditions and to evaluate novel CKD therapies, and the UUO model described here is the clearest example of how that looks in practice.
The UUO model involves surgically obstructing one ureter, which creates a controlled buildup of pressure in the kidney and leads to fibrosis, a hallmark of CKD. The tubules take the mechanical load first, with interstitial inflammation and fibroblast activation following, and the model keeps that sequence visible and timeable. In cynomolgus monkeys the model has two advantages over traditional rodent models. The genetic makeup is similar to humans, so the response to disease and treatment translates, and that also allows testing of next-generation therapies such as gene and antibody treatments, which are often species-specific and may not cross-react effectively with rodent proteins. Fibrosis also progresses more like human pathology: the study on Prisys Biotech's UUO model shows advanced tubulointerstitial fibrosis developing within six weeks, which gives a flexible disease window for testing therapeutic efficacy and tracking disease progression.
Key Findings From The UUO Model Study
Prisys Biotech's research on the UUO model, conducted in collaboration with UCB Pharma, produced several findings that show what the model is good for.
- Histology close to human disease. The study found marked thickening of the tubular basement membrane, extensive collagen accumulation, and tubular atrophy, accompanied by fibroblast infiltration and increased transglutaminase 2 (TG2) activity, both characteristic markers of kidney fibrosis in human CKD patients.
- Measurable biomarkers. Collagen levels, TG2 activity, and hydroxyproline content (a collagen marker) let researchers quantify fibrosis progression. TG2 activity increased markedly after three weeks, and extracellular TG2 peaked by week four, which marks that window as the point to evaluate anti-fibrotic therapies before fibrosis plateaus. That timing is what turns a biomarker into a decision point, because before week three the signal is still building and after the plateau a treatment effect is harder to separate from background.
- TG2 as a mechanistic target. TG2 is an enzyme that promotes fibrosis by cross-linking extracellular matrix proteins, and it correlated strongly with fibrosis markers in the UUO model. Because TG2 acts on the matrix rather than on a single receptor, a candidate's effect appears in the collagen readouts as well as in TG2 activity, which gives a study two ways to check the same claim.
Using The UUO Model In A Drug Development Program
Prisys Biotech's UUO model in cynomolgus monkeys is a working asset for pharmaceutical and biotech companies developing kidney disease therapies. It gives precise evaluation of human-specific therapies, which suits biologics and antibody-based treatments that may not be compatible with rodent models. It also gives detailed tracking of disease progression, because the timeline and the measurable biomarkers support efficacy testing in both early and later stages of fibrosis.
With these renal disease models, pharmaceutical and biotech companies can run preclinical assessments that support the development of kidney disease treatments. The same platform sits inside the Nephrology disease area. For more information or to discuss specific research needs, contact Prisys Biotech to arrange a consultation.
